NCT05403502已完成不适用
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 183
- 试验地点
- 25
- 主要终点
- Diabetic Ketoacidosis
研究概览
简要总结
Prospective, multi-center, single-arm study in adults and children ages 6 to 80 with type 1 diabetes to evaluate the safety of Lyumjev with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin pump.
详细描述
This is a prospective, multi-center, single-arm study in adults and children (ages 6 to 80 years) with type 1 diabetes who are current users of the t:slim X2 insulin pump with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin pump. After a run-in period, participants will use the study pump with Control-IQ technology 1.5 and Lyumjev insulin for a 3-month outpatient treatment period. Up to 200 participants will be enrolled so at least 160 complete the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 6 to <81 years
- •Diagnosis of type 1 diabetes for at least 1 year
- •Currently using Control-IQ technology for at least 3 months, with CGM data recorded indicative of system use (active closed loop) for at least 85% of the possible time in 14 days prior to enrollment
- •Total daily insulin dose (TDD) at least 2 U/day
- •HbA1c < 10.5%
- •Residing full-time in the United States, with no anticipated travel outside the United States during the period of study participation.
- •For participants <18 years old, living with one or more parent/legal guardian knowledgeable about emergency procedures for severe hypoglycemia and able to contact the participant in case of an emergency, and willing to use the Dexcom Follow app (with push notifications turned on) for the duration of the study.
- •If >18 years old, participant has someone who lives within 30 minutes of them who is willing to be contacted if the study team can't reach the participant in case of a suspected medical emergency.
- •Participant has agreed to participate in the study; and has read, understood and signed the informed consent form (ICF) and assent, if applicable; and has agreed to follow all study procedures, including:
- •suspending use of any personal CGM for the duration of the clinical trial once the study CGM is in use
- •switching to or continuing to use Humalog during the lead-in period
- •switching to Lyumjev for the main study period.
- •willing and able to perform the study exercise and meal challenges.
- •Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol, including ability to respond to alerts and alarms, and to provide basic diabetes self-management.
- •Participant and/or parent/legal guardian have the ability to read and understand English
排除标准
- •More than 1 episode of diabetic ketoacidosis (DKA) in the past 6 months
- •More than 1 episode of severe hypoglycemia (needing assistance) in the past 6 months
- •Inpatient psychiatric treatment in the past 6 months
- •History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to screening or unwillingness to agree to abstain from illicit drugs throughout the study.
- •For Female: Currently pregnant or planning to become pregnant during the time period of study participation
- •A negative pregnancy test will be required for all females of child-bearing potential (menarchal)
- •Counseling on appropriate birth control options will be provided to females with child-bearing potential in the event the participant does not have an acceptable plan.
- •Adults lacking the capacity to provide consent and/or follow study procedures in the opinion of the investigator
- •Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas).
- •Hemophilia or any other bleeding disorder
- •Hemoglobinopathy
- •History of heart, liver, lung or kidney disease determined by investigator to interfere with the study
- •History of allergic reaction to Humalog or Lyumjev
- •Use of glucocorticoids, beta blockers or other medications determined by investigator to interfere with study
- •Abnormal screening electrocardiogram consistent with increased risk during exercise, such as arrhythmia, ischemia, or prolonged QTc interval (>450 ms) (Screening ECG only required for participants age > 50 years, duration of diabetes > 20 years, or history of coronary artery disease)
- •Significant chronic kidney disease (which could impact CGM accuracy in investigator's judgment) or hemodialysis
- •History of adrenal insufficiency
- •History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated
- •History of gastroparesis
- •A condition, which in the opinion of the investigator or designee, would put the participant or study at risk
- •Participation in another pharmaceutical or device trial at the time of enrollment or anticipated for during the time period of study participation
- •Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., Eli Lilly and Co., or TypeZero Technologies, LLC, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
结局指标
主要结局
Diabetic Ketoacidosis
时间窗: 15 weeks
Number of diabetic ketoacidosis events requiring an overnight hospitalization and diagnosis by a doctor.
Severe Hypoglycemia
时间窗: 15 weeks
Number of severe hypoglycemia events (with cognitive impairment such that assistance of another individual is needed for treatment) during study
Unanticipated Adverse Device Effects
时间窗: 15 weeks
Number of unanticipated adverse device effects (UADE) events
次要结局
- Overall Percent Time Less Than 70 mg/dL(15 weeks)
- Overall Percent Time Less Than 54 mg/dL(15 Weeks)
- Postprandial Percent Time Less Than 70 mg/dL, Through 4 Hours After Each Meal(during 4 hour postprandial period after each meal, up to 15 weeks)
- Postprandial Percent Time Less Than 54 mg/dL, Through 4 Hours After Each Meal(during 4 hour postprandial period after each meal, up to 15 weeks)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
不适用
Feasibility Study of a Transdermal Continuous Glucose Monitoring (CGM) System in Diabetic PatientsDiabetesNCT05133973EyeSense GmbH15
已完成
不适用
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 DiabetesType 1 DiabetesNCT02660827Medtronic Diabetes151
已完成
不适用
Diabeloop for Highly Unstable Type 1 DiabetesDiabetes Mellitus, BrittleClosed-LoopDiabetes Mellitus, Type 1NCT04042207Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète7
已完成
不适用
Hybrid Closed Loop Pivotal Trial in Type 1 DiabetesType 1 DiabetesNCT02463097Medtronic Diabetes124
已完成
不适用
Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA)Type 1 DiabetesNCT02061488Rennes University Hospital10